2 Days. Real Options Skills.
Join options trader Ben Sturgill as he reveals his most reliable options strategies - live. Seats are limited.
Save your seatTrader's Perspective
CV ran from roughly $4.88 in mid-March to about $7.50 by mid-May as traders shifted from the March private placement to the mid-year Food and Drug Administration clearance story for its AI-assisted reading module.
A failure to hold $6.50 has the potential to send CV back toward $5.50 to $4.90. Any delay on the Food and Drug Administration review or more financing overhang from the March resale registration would accelerate the downside.
If CV holds the $6.50 to $6.80 area, a move back toward $7.50 to $8.50 is on the table as long as volume improves and the AI clearance setup stays intact. Resistance around $7.50 is the first hurdle.
Analyst Ratings
CapsoVision Inc. Earnings
We don't currently have information about CapsoVision Inc.'s earnings.